Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Olympics Are A “Wild Card” For Supplement Industry Publicity

This article was originally published in The Tan Sheet

Executive Summary

The Olympics inspire fitness enthusiasts to improve performance, which could translate to higher sales of legitimate supplements, but if athletes blame supplements for drug testing violations, the industry incurs bad publicity and consumer confidence slips.

You may also be interested in...



U.S. Military Investigates Supplement Ingredient DMAA, Bans Sales

DoD suspends DMAA sales at military stores after regulators in Canada and New Zealand restricted access and as some U.S. firms change how they market and label the ingredient. These moves and the potential for an FDA review could lead to enforcement against DMAA similar to the 2004 ban against ephedra’s use in supplements.

FDA Supplement Enforcement Priorities Go Beyond NDI Notification

FDA’s plan to tighten enforcement of new dietary ingredient notifications with its controversial guidance still in draft form raises concerns for some stakeholders.

FDA, Trade Groups Team Up To Bolster Enforcement On Tainted Supplements

FDA threatens to take "swift and strong" enforcement action without warning, including filing criminal charges, against manufacturers, suppliers and distributors of tainted supplements, according to a letter sent to industry Dec. 15.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel